Marion reconsidering a move to Puerto Rico?
While emphasizing that the firm will not make any commitments until the picture on Sec. 936 clears, Marion Exec VP Michael Herman acknowledged that "Puerto Rico certainly is a viable alternative." Herman said the company won't need additional manufacturing capacity for "24 months or so, and hopefully before then the issue will be decided by the Treasury." Herman added that the recent tax simplification proposal from Treasury, in its present form, could add up to $7 mil. to Marion's bottom line if R&D credits remain
You may also be interested in...
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.